Methods for treating liver tissue

A technology of liver tissue and hepatic artery, applied in tissue regeneration, application, pharmaceutical formulation, etc., can solve the problem that non-targeted therapy is not particularly effective

Pending Publication Date: 2018-07-31
HANGZHOU RAYGENE PHARM CO LTD
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Non-targeted therapies for liver treatment, such as conventional chemotherapy and radiation therapy, are not particularly effective and carry risks including systemic exposure to chemotherapeutic agents and ionizing radiation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for treating liver tissue
  • Methods for treating liver tissue

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0095] According to the following examples, local infusion of a hypoxia-activated bioreductant followed by embolization when the hepatic artery pressure is reduced will result in necrosis of liver tumors. A 4-French vascular catheter will cannulate the main branch of the hepatic artery supplying the targeted liver cancer lesion. A balloon microcatheter (3-French or smaller) will then be inserted through the 4-French vascular catheter already in place. A small microcatheter is then cannulated into the branch of the artery supplying the targeted lesion. An arteriogram will be performed to ensure that the position of the microcatheter tip is in the correct position for the subsequent injection of a hypoxic activator followed by lipiodol injection. Once the balloon catheter is confirmed to be properly positioned, the balloon is inflated to stop or slow blood flow, thereby reducing pressure in the artery beyond the balloon tip. The hypoxia-activated bioreductant tirapazamine will...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Shore hardnessaaaaaaaaaa
lengthaaaaaaaaaa
Login to view more

Abstract

Methods and kits are provided for administering a hypoxia-activated bioreductive agent by applying the agent locally to liver tissue when hepatic arterial pressure is reduced. Local arterial application when pressure is reduced tissue prolongs the duration of tissue exposure to the hypoxia-activated bioreductive agent. Hepatic pressure may be reduced proximal to the liver tissue. In some embodiments, local application may be followed by embolization when arterial pressure is reduced. Embolization under reduced pressure may decrease complications associated with backflow and increase the efficacy of the hypoxia-activated agent.

Description

[0001] cross reference [0002] This PCT application claims priority to U.S. Provisional Patent Application No. 62 / 336,498 filed May 13, 2016, which is hereby incorporated by reference in its entirety for all purposes. Background technique [0003] Liver cancer can originate in the liver or derive from metastatic cancer in other organs, such as from colorectal, breast, or lung cancers. The most common type of liver cancer is hepatocellular carcinoma [0004] (HCC), accounting for approximately 75% of all liver cancers. Other types of liver cancer include fibrolamellar hepatocellular carcinoma, cholangiocarcinoma, and angiosarcoma. [0005] Liver cancer is the fifth leading cause of cancer-related death in the world. The highest incidence in the world is in Asia, which accounts for the majority of all known liver cancer incidence worldwide. In Asia, very high incidence rates can be seen in China, Korea, and Japan, with some registries showing rates higher than 20 / 100,000 i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K31/135A61K45/00A61K45/06A61P35/00A61P43/00
CPCA61K9/00A61K45/00A61L29/16A61K9/0019A61K33/18A61L2300/416A61K31/53A61K31/135A61K31/167A61P43/00A61P35/00A61P1/16A61B17/12109A61B17/12136A61B17/12186A61K9/0024A61L24/0015A61M25/10A61L2430/36A61B17/12181
Inventor 李瑞民
Owner HANGZHOU RAYGENE PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap